Información del artículo
El Texto completo está disponible en PDF
Bibliogrífia
[1.]
V. Moreno, J.R. González, M. Soler, F.X. Bosch, M. Kogevinas.
Borràs JM. Estimación de la incidencia del cáncer en España: período 1993-1996.
Gac Sanit, 15 (2001), pp. 380-388
[2.]
C. Tomeo, G.A. Colditz, W.C. Willet, E. Giovannucci, E. Plata, B. Rockhill, et al.
Harvard report on cancer prevention: prevention of colon cancer in United States.
Cancer Causes Control, 10 (1999), pp. 167-180
[3.]
S.J. Winawer, R.H. Fletcher, L. Miller, F. Gopdlee, M.H. Stolar, C.D. Mulrow, et al.
Colorectal cancer screening: clinical guidelines and rationale.
Gastroenterology, 112 (1997), pp. 594-642
[4.]
A. Lang, D. Ransohoff.
What can we conclude from the randomized controlled trials for fecal occult blood test screening.
Eur J Gastroenterol Hepatol, 10 (1998), pp. 199-204
[5.]
B. Towler, L. Irving, P. Glasziou, J. Kewenter, D. Weller, C. Stagy.
A systematic review of the effect of screening for colorectal cancer using the fecal occult blood test, Hemoccult.
BMJ, 371 (1998), pp. 559-565
[6.]
J.S. Mandel, T.R. Church, F. Ederer.
The effect of fecal occultblood screening on the incidence of colorectal cancer.
N Engl J Med, 344 (2001), pp. 1022-1023
[7.]
D.F. Ransohoft, R.J. Soudler.
Screening for colorectal cancer.
N Emgl J Med, 346 (2002), pp. 40-44
[8.]
M.J. Atkin, J. Cuzik, J.M.A. Northover, D.K. Whynes.
Prevention of colorectal cancer by once-only sigmoidoscopy.
Lancet, 341 (1993), pp. 736-740
[9.]
A.L. Frazier, G.A. Colditz, C.S. Fuchs, K.M. Kuntz.
Cost-effectiveness of screening for colorectal cancer in the general population.
JAMA, 284 (2000), pp. 1954-1961
[10.]
D.K. Whynes, A.R. Neilson, A.R. Walker, J.D. Hardcastle.
Faecal occult blood screening for colorectal cancer: is it cost-effective?.
Health Econ, 7 (1998), pp. 21-29
[11.]
Canadian task force on Preventive Health Care.
Colorectal cancer screening.
Canadian Med Assoc J, 165 (2001), pp. 206-208
Copyright © 2002. Sociedad Española de Salud Pública y Administración Sanitaria
